Filing Flows › aTYR Pharma (ATYR) › Q3 2025
aTYR Pharma (ATYR) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
aTYR Pharma (ATYR) reported revenue of $190K for the third quarter 2025 (Q3 2025).
aTYR Pharma, Q3 2025: revenue $190K, net loss $25.7M, operating cash flow −$20.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $190K | — | — |
| Operating profit | −$26.7M | — | — |
| Net earnings | −$25.7M | — | — |
| Operating cash flow | −$20.5M | — | — |
What changed
Revenue was $190K in Q3 2025.
Operating costs exceeded revenue by $26.7M, an operating margin of -14076.3%. The quarter ended with a net loss of $25.7M. Minority interests bore $2K of it: to shareholders the quarter was a loss of $25.7M.
Operating cash flow was −$20.5M. Non-cash charges added back $165K of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items added $3.8M. Capital expenditures of $37K exceeded it, leaving free cash flow of −$20.5M.
Questions
What was aTYR Pharma's revenue in the third quarter 2025?
aTYR Pharma (ATYR) reported revenue of $190K for the third quarter 2025 (Q3 2025).
Source: aTYR Pharma 10-Q on SEC EDGAR.